Connect your AI

Design Therapeutics, Inc. DSGN Debt-to-assets

Debt-to-assets at other companies

ALN

Alnylam PharmaceuticalsALNY

0.1×0.0×

Intellia TherapeuticsNTLA

0.1×0.0×

CRISPR TherapeuticsCRSP

0.3×+0.2×

Dyne Therapeutics, Inc.DYN

0.2×+0.1×

Vor BiopharmaVOR

0×-0.3×

Taysha Gene Therapies, Inc.TSHA

0.2×-0.2×

Other financials

Income statement

Revenue-—

Operating income-$19.7M+3.5%

Net income-$17.6M+0.4%

EPS (diluted)-$0.29+6.5%

Balance sheet

Cash & equivalents$12.8M-6.6%

Total debt$2.7M+27.7%

Total equity$218.1M-4.3%

Total assets$230.4M-3.0%

Cash flow

Operating cash flow-$16.4M+2.1%

CapEx--100%

Free cash flow-$16.4M+2.6%

Valuation

Market cap$860.66M+295%

Enterprise value$850.62M+313%

Profitability

Operating margin-3,685.8%—

Net margin-3,663.7%—

Returns & leverage

Return on equity-31.3%+19.5pp

Debt / equity0×0.0×

Current ratio22.3×-6.1×

Where this comes from

Calculated from Design Therapeutics, Inc.’s reported figures.

total debt/total assets=0×

Based on the most recent quarter.

The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Design Therapeutics, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Design Therapeutics, Inc.'s debt-to-assets?: Design Therapeutics, Inc. (DSGN) reported debt-to-assets of 0× in Q1 2026.
How has Design Therapeutics, Inc.'s debt-to-assets changed year-over-year?: Design Therapeutics, Inc.'s debt-to-assets increased by 32.2% year-over-year, from 0× to 0×.
What is the long-term trend for Design Therapeutics, Inc.'s debt-to-assets?: Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s debt-to-assets has grown at a -7.5% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?: Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.